Craig Crews, Mikael Dolsten get $32M for Quarry Thera Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

Mon T W Th F 24 November, 2025

Biopharma’s year doesn’t start on January 1. It starts in San Francisco. Join Endpoints for bold conversations with the leaders shaping what's next. Plus, get access to the Endpoints Hub — our premium coworking and meeting space just steps from the action. Save $200 with Early Bird rates — reserve your spot today.

presented by Start smarter, dis­cov­er faster: EM­Ly Co-pi­lot, an AI-dri­ven bi­o­log­ics dis­cov­ery plat­form

news Novo Nordisk's semaglutide misses in closely-watched Alzheimer’s trials Bayer’s stock rallies as next-gen blood thinner beats the odds with Phase 3 win Exclusive: Craig Crews, Mikael Dolsten get $32M for Quarry Thera, with plans for more biotechs Nobel laureate Carolyn Bertozzi to rejoin Lilly board

Dec 02 1:00pm ET Navigating JPM 2026: Biotech/biopharma trends, policy impacts & a forward look into the year sponsored by Real Chemistry Dec 03 10:30am ET AI & multi-omics for translational research sponsored by Precision for Medicine Dec 09 11:00am ET Strategic solutions for cost, time and quality challenges in drug development sponsored by Cambrex Dec 16 11:30am ET Maintaining EU GMP Annex I expectations while adopting new standards for prefilled syringe systems sponsored by Grand River Dec 17 12:00pm ET Genetic cohorting and therapeutic response in CKD: Real-world insights from RenasightIQ™ sponsored by Natera

Our latest survey captured the bleakest biotech outlook in a decade — but is recent momentum real or a mirage? Join us to hear what CEOs are saying about the industry’s direction. Sign up now.

endpoints pharma More drama surrounds FDA as top aide to Makary faces pushback from White House AstraZeneca to onshore rare disease portfolio as part of its $50B pledge to the US Novo, Lilly begin to sell obesity medications directly to employers Teva loses IRA drug pricing challenge in DC federal court

in case you missed it 1. Lilly becomes first $1 trillion pharma company 2. FDA investigates child death potentially related to Takeda's enzyme replacement therapy 3. Peer Review Jeff Bluestone, Stephen Dilly talk CEO handoff, what’s next for Sonoma; Scott Gottlieb's next move 4. News Briefing Sarepta ends Elevidys trial with Hansa's pre-treatment; Some pipeline cuts at Moderna 5.